1
|
Imanishi M, Inoue T, Fukushima K, Yamashita R, Nakayama R, Nojima M, Kondo K, Gomi Y, Tsunematsu H, Goto K, Miyamoto L, Funamoto M, Denda M, Ishizawa K, Otaka A, Fujino H, Ikeda Y, Tsuchiya K. CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses. J Pharmacol Sci 2023; 153:232-242. [PMID: 37973221 DOI: 10.1016/j.jphs.2023.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 09/25/2023] [Accepted: 10/13/2023] [Indexed: 11/19/2023] Open
Abstract
A strong hypoxic environment has been observed in pancreatic ductal adenocarcinoma (PDAC) cells, which contributes to drug resistance, tumor progression, and metastasis. Therefore, we performed bioinformatics analyses to investigate potential targets for the treatment of PDAC. To identify potential genes as effective PDAC treatment targets, we selected all genes whose expression level was related to worse overall survival (OS) in The Cancer Genome Atlas (TCGA) database and selected only the genes that matched with the genes upregulated due to hypoxia in pancreatic cancer cells in the dataset obtained from the Gene Expression Omnibus (GEO) database. Although the extracted 107 hypoxia-responsive genes included the genes that were slightly enriched in angiogenic factors, TCGA data analysis revealed that the expression level of endothelial cell (EC) markers did not affect OS. Finally, we selected CA9 and PRELID2 as potential targets for PDAC treatment and elucidated that a CA9 inhibitor, U-104, suppressed pancreatic cancer cell growth more effectively than 5-fluorouracil (5-FU) and PRELID2 siRNA treatment suppressed the cell growth stronger than CA9 siRNA treatment. Thus, we elucidated that specific inhibition of PRELID2 as well as CA9, extracted via exhaustive bioinformatic analyses of clinical datasets, could be a more effective strategy for PDAC treatment.
Collapse
Affiliation(s)
- Masaki Imanishi
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan.
| | - Takahisa Inoue
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan; Department of Pharmacy, Tokushima University Hospital, Japan
| | - Keijo Fukushima
- Department of Pharmacology for Life Sciences, Graduate School of Biomedical Sciences, Tokushima University, Japan.
| | - Ryosuke Yamashita
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Ryo Nakayama
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Masataka Nojima
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Kosuke Kondo
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Yoshiki Gomi
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Honoka Tsunematsu
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Kohei Goto
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Licht Miyamoto
- Laboratory of Pharmacology and Food Science, Department of Nutrition and Life Science, Faculty of Health and Medical Sciences, Kanagawa Institute of Technology, Japan
| | - Masafumi Funamoto
- Department of Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Masaya Denda
- Department of Bioorganic Synthetic Chemistry, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Keisuke Ishizawa
- Department of Pharmacy, Tokushima University Hospital, Japan; Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Japan; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Japan
| | - Akira Otaka
- Department of Bioorganic Synthetic Chemistry, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Hiromichi Fujino
- Department of Pharmacology for Life Sciences, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Yasumasa Ikeda
- Department of Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| | - Koichiro Tsuchiya
- Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Japan
| |
Collapse
|